340B Compliance for Specialty Pharmacy: What Health Systems Need to Know in 2026

‍

There’s been a noticeable shift in how people talk about 340B compliance. Not long ago, it was something many organizations felt they had a handle on. Now, it’s a constant point of concern, especially for teams managing a 340B specialty pharmacy.

Part of that shift comes down to visibility. Regulators are looking closer, manufacturers are pushing harder, and 340B audits are showing up more often and going deeper when they do. For health systems, that means the margin for error is shrinking.

Specialty pharmacy only amplifies that pressure. The drugs are expensive, the workflows are complex, and the expectations around documentation are higher. When something breaks, it’s rarely small. That’s why specialty pharmacy compliance has become such a critical focus area going into 2026.

What’s also changing is the broader environment. Updates to 340B compliance requirements, evolving payer dynamics, and ongoing policy uncertainty are forcing organizations to rethink how they approach 340B compliance from the ground up.

What Is 340B Compliance in Specialty Pharmacy?

At a basic level, the 340B program hasn’t changed. Covered entities still purchase outpatient drugs at discounted prices, and those savings are meant to support patient care. But in a 340B specialty pharmacy, the day-to-day reality is far more complicated.

Here, 340B compliance is about proving that every transaction holds up under scrutiny. That includes confirming patient eligibility, ensuring accurate billing pathways, and preventing duplicate discounts. It also means being ready to explain those decisions during 340B audits, sometimes long after the fact.

The challenge is that specialty pharmacy doesn’t operate in a single lane. Data flows across clinical systems, pharmacy platforms, and billing environments. That fragmentation makes specialty pharmacy compliance harder to manage consistently.

And when you layer in the cost of these medications, the stakes rise quickly. Even a small breakdown in process can lead to findings during a 340B compliance audit.

‍

Why 340B Compliance Is Uniquely Challenging for Specialty Pharmacy

The financial weight of specialty drugs changes how organizations experience risk. In retail settings, errors can add up over time. In a 340B specialty pharmacy, a single mistake can be significant on its own. That’s one reason 340B compliance feels more urgent in this space.

Another issue is the split between pharmacy and medical benefits. Specialty drugs don’t always follow a single billing path. Tracking eligibility across those pathways is one of the more persistent gaps teams run into during 340B audits.

Contract pharmacy relationships add another layer. Many health systems rely on them, but oversight has become more complicated. Manufacturer restrictions and shifting state laws mean that maintaining 340B compliance across these networks requires constant attention. It’s also an area frequently examined during a 340B compliance audit.

Biosimilars introduce additional complexity. Switching between therapies can affect pricing, reimbursement, and eligibility, all of which tie back to 340B compliance requirements. Without clear processes, these transitions can create inconsistencies that surface later during audits.

The 2026 Regulatory Landscape: What’s Changed for 340B Specialty Pharmacy 

The current environment isn’t settled, it’s evolving.

The HRSA rebate model is a good example. While it’s been paused, it hasn’t disappeared. If it returns, it could shift how 340B compliance is validated, moving more responsibility to post-dispense reconciliation. For a 340B specialty pharmacy, that would mean rethinking how transactions are tracked.

The Inflation Reduction Act is also influencing the landscape. Changes in drug pricing may reduce margins for certain therapies, which could affect how much value organizations see from their 340B specialty pharmacy programs.

There’s also increased attention on transparency. As expectations around documentation grow, so do the demands tied to 340B audit requirements. Health systems are finding that what worked a few years ago no longer meets today’s standards.

At the same time, legal battles around contract pharmacies continue to create uncertainty. This makes it harder to maintain consistent 340B compliance across different regions, particularly for larger systems.

Specialty Pharmacy 340B Compliance: The 7 Critical Requirements

Most teams don’t need a theoretical framework, they need clarity on what actually matters. A practical 340B compliance checklist usually starts with patient eligibility. If that foundation isn’t solid, everything else becomes harder to defend during 340B audits.

Duplicate discount prevention is another constant concern. Specialty drugs often intersect with Medicaid, and ensuring there’s no overlap is a core part of meeting 340B audit requirements.

Contract pharmacy oversight remains under heavy scrutiny. It’s not enough to have agreements in place; organizations need to demonstrate active management and alignment with 340B compliance requirements.

Inventory management and split-billing processes also carry significant weight. When systems don’t align, discrepancies show up and those are often uncovered during a 340B compliance audit.

Buy-and-bill scenarios add complexity on the medical side. These transactions must still meet 340B compliance standards, even though the workflows differ from traditional pharmacy claims.

Audit readiness, in reality, is continuous. Teams that treat it as a periodic effort often struggle when 340B audits actually happen. Many organizations are now turning to a 340B independent audit to proactively identify gaps before regulators do.

Finally, recertification and self-disclosure play an important role. While they may feel administrative, they are essential to maintaining long-term 340B compliance.

How Technology Solves Specialty Pharmacy 340B Compliance

If there’s one recurring issue across organizations, it’s fragmentation. Data lives in too many places, which makes it harder to maintain consistent 340B compliance.

That’s where unified platforms come in. By bringing together clinical, pharmacy, and financial data, they give teams a clearer picture of what’s happening inside a 340B specialty pharmacy.

AI is starting to help as well, though in practical ways rather than abstract ones. It can flag inconsistencies, identify risks, and support 340B compliance audit efforts by surfacing issues early. This becomes especially useful when preparing for 340B audit requirements that demand detailed documentation.

There’s also the opportunity side. Without strong visibility, organizations often miss eligible prescriptions. Improving capture rates is one of the more immediate ways to strengthen both compliance and financial performance.

For many teams, a 340B compliance checklist is no longer enough on its own. Technology is what makes it actionable at scale.

Getting Started: A Specialty Pharmacy 340B Optimization Roadmap

Most organizations already have pieces of the puzzle in place. The challenge is connecting them.

The first step is understanding where things stand. That means identifying gaps in 340B compliance, especially in areas that frequently come up during 340B audits.

From there, it helps to focus on high-impact drugs. Specialty medications with the highest cost tend to reveal the biggest opportunities and the biggest risks.

Technology decisions should follow workflow needs. Tools that support specialty pharmacy compliance and align with real processes tend to deliver better outcomes than standalone solutions.

Finally, ongoing monitoring is what sustains progress. Some organizations are also incorporating a 340B independent audit into their strategy, using it as a checkpoint rather than a reaction.

Over time, this approach makes 340B compliance feel less like a scramble and more like a controlled, manageable process.

FAQs

Q1: What is 340B compliance for specialty pharmacy?

It involves ensuring that medications dispensed through a 340B specialty pharmacy meet eligibility criteria, avoid duplicate discounts, and align with all 340B compliance requirements.

Q2: How does the IRA affect specialty pharmacy 340B savings?

The IRA may influence drug pricing and reimbursement, which can affect savings generated through 340B compliance programs.

Q3: What is the HRSA 340B rebate pilot?

It’s a proposed model that could shift how discounts are applied, increasing the importance of tracking and 340B compliance audit processes.

Q4: How do manufacturer restrictions affect specialty pharmacy 340B?

They can limit contract pharmacy operations, making it harder to maintain consistent specialty pharmacy compliance.

Q5: What percentage of 340B audits find compliance issues?

A large portion of 340B audits identify at least one issue, often tied to eligibility or duplicate discounts.

Q6: How can health systems increase specialty drug 340B capture rates?

Better data integration, stronger workflows, and alignment with a 340B compliance checklist can improve capture.

Q7: What technology do specialty pharmacies need for 340B compliance?

They benefit from unified platforms, automation tools, and systems designed to meet evolving 340B audit requirements.

‍